Biotech Values

[dewophile]

better than ibrance?

i think NVS has a good CDK4/6 too could end up being a fairly crowded field

regardless for a pharma their size they do have a lot of eggs in the AD basket as DD said

PS: ibrance is a good example of a drug that took forever to get to market but is a winner. Let's hope FG-3019 can follow a similar pattern! (i know several here have been skeptical on the drug just based on how slow development has gone for 3019)